智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300122 智飞生物

交易中 05-08 14:41:48

{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":36.39,"timestamp":1715150508000,"preClose":36.88,"halted":0,"volume":19458791,"delay":0,"floatShares":1414000000,"shares":2394000000,"eps":3.1313,"marketStatus":"交易中","marketStatusCode":2,"change":-0.49,"latestTime":"05-08 14:41:48","open":36.89,"high":37.29,"low":36.3,"amount":714000000,"amplitude":0.0268,"askPrice":36.4,"askSize":22,"bidPrice":36.39,"bidSize":21,"shortable":0,"etf":0,"ttmEps":3.1313,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1715151600000},"adr":0,"adjPreClose":36.88,"symbolType":"stock","openAndCloseTimeList":[[1715131800000,1715139000000],[1715144400000,1715151600000]],"highLimit":40.57,"lowLimit":33.19,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"pbRate":2.7,"roa":"--","roe":"4.52%","epsLYR":3.3624,"committee":-0.208824,"marketValue":87110000000,"floatMarketCap":51467000000,"peRate":11.621371,"changeRate":-0.0133,"turnoverRate":0.0138,"status":1},"requestUrl":"/m/hq/s/300122/","defaultTab":"news","newsList":[{"id":"2431129483","title":"智飞生物：公司严格遵守法律法规履行纳税义务。财务数据详情请查阅公司定期报告披露的相关内容","url":"https://stock-news.laohu8.com/highlight/detail?id=2431129483","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431129483?lang=zh_cn&edition=full","pubTime":"2024-04-30 19:03","pubTimestamp":1714474986,"startTime":"0","endTime":"0","summary":"公司产品的销售推广情况请持续关注公司定期报告，感谢关注！公司严格遵守会计准则要求及公司会计政策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000045793.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431857117","title":"智飞生物最新公告：26价肺炎球菌结合疫苗获临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2431857117","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431857117?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:01","pubTimestamp":1714395703,"startTime":"0","endTime":"0","summary":"智飞生物公告，由公司全资子公司智飞绿竹自主研发的26价肺炎球菌结合疫苗获得国家药品监督管理局药物临床试验批准通知书，同意本品在2月龄及以上人群中开展临床试验。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900030897.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431333857","title":"智飞生物(300122.SZ)：26价肺炎球菌结合疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2431333857","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431333857?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:00","pubTimestamp":1714395600,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，公司近日收到全资子公司北京智飞绿竹生物制药有限公司(简称“智飞绿竹”)报告，由智飞绿竹自主研发的26价肺炎球菌结合疫苗(简称“26价肺炎结合疫苗”)获得国家药品监督管理局药物临床试验批准通知书，同意本品在2月龄及以上人群中开展临床试验。公司将根据临床试验批准通知书的要求，尽快开展相关临床试验工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1115048.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431025285","title":"平安证券：给予智飞生物增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431025285","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431025285?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:52","pubTimestamp":1714359122,"startTime":"0","endTime":"0","summary":"平安证券股份有限公司叶寅,倪亦道近期对智飞生物进行研究并发布了研究报告《HPV疫苗进一步放量，带疱疫苗即将贡献新增量》，本报告对智飞生物给出增持评级，当前股价为35.58元。　　维持“推荐”评级。当前预测下，公司24年8.7xPE，估值与纯渠道企业趋同，微卡等自产产品的潜力价值未充分反映，维持“推荐”评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为65.0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900007405.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430021324","title":"疫苗龙头，没了2800亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2430021324","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2430021324?lang=zh_cn&edition=full","pubTime":"2024-04-25 20:25","pubTimestamp":1714047925,"startTime":"0","endTime":"0","summary":"高光不再","market":"sg","thumbnail":"https://img3.gelonghui.com/d4adc-abc3c929-b511-4371-8478-b21853917ecb.png?guru_height=546&guru_width=707","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/d4adc-abc3c929-b511-4371-8478-b21853917ecb.png?guru_height=546&guru_width=707"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/723988","is_publish_highlight":false,"gpt_icon":0},{"id":"2430402125","title":"疫苗江湖风起云涌，智飞生物“一哥”地位难保","url":"https://stock-news.laohu8.com/highlight/detail?id=2430402125","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2430402125?lang=zh_cn&edition=full","pubTime":"2024-04-25 20:06","pubTimestamp":1714046760,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　在“疫苗一哥”智飞生物发布2023年年报后，其股价便连续下跌，有市场人士则将其下跌的股价，与其高度依赖的国外供应商和逐渐显露的业绩颓势联系在一起。　　近几年来，疫苗市场风云变幻，一方面，曾经的“爆款”九价HPV疫苗不再一针难求；另一方面，国产九价HPV疫苗各种好消息不断传出，引来不少机构对其上市进程的高度关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2024-04-25/doc-inataefs7380124.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-04-25/doc-inataefs7380124.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429178140","title":"智飞生物（300122）4月23日主力资金净卖出1.36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429178140","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429178140?lang=zh_cn&edition=full","pubTime":"2024-04-24 09:15","pubTimestamp":1713921349,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月23日收盘，智飞生物报收于35.39元，下跌11.99%，换手率5.52%，成交量78.08万手，成交额27.4亿元。近5日资金流向一览见下表：智飞生物融资融券信息显示，融资方面，当日融资买入2.12亿元，融资偿还2.27亿元，融资净偿还1566.35万元。智飞生物主营业务：疫苗、生物制品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400018361.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429158060","title":"一季度净利润同比下降！智飞生物跌近15%，公司回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2429158060","media":"21世纪经济报道","top":-1,"share":"https://www.laohu8.com/m/news/2429158060?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:54","pubTimestamp":1713851640,"startTime":"0","endTime":"0","summary":"　　南方财经4月23日电，智飞生物 低开后一路走低，截至早盘收盘，跌14.67%，报34.31元。消息面上，智飞生物今年第一季度营业收入113.96亿元，同比增长2%；归母净利润14.58亿元，同比下降28.26%。对于一季度利润下降，智飞生物并未在公告中说明原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-23/doc-inasuzcy8991754.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-23/doc-inasuzcy8991754.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429133892","title":"智飞生物低开低走盘中跌超14% 一季度净利跌近三成","url":"https://stock-news.laohu8.com/highlight/detail?id=2429133892","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2429133892?lang=zh_cn&edition=full","pubTime":"2024-04-23 10:23","pubTimestamp":1713838980,"startTime":"0","endTime":"0","summary":"　　4月23日消息，智飞生物低开低走，截至发稿，跌14.40%，报34.42元/股，成交额14.33亿元，总市值823.9亿元。　　消息面上，4月22日晚间，重庆智飞生物制品股份有限公司发布2023年度业绩报告，全年营业收入约529.18亿元，同比增长38.3%；归母净利润约80.7亿元，同比增加7.04%；归母扣非净利润79.15亿元，同比增长5.4%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/2024-04-23/doc-inasuqpz0184059.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/2024-04-23/doc-inasuqpz0184059.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429855331","title":"智飞生物一季度净利跌近三成，去年九价HPV疫苗批签发量增超1.3倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2429855331","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2429855331?lang=zh_cn&edition=full","pubTime":"2024-04-23 07:52","pubTimestamp":1713829920,"startTime":"0","endTime":"0","summary":"　　“疫苗茅”智飞生物2023年营收净利维持了双增的态势，但今年第一季度的业绩表现不太好。　　4月22日晚间，重庆智飞生物制品股份有限公司发布2023年度业绩报告，全年营业收入约529.18亿元，同比增长38.3%；归母净利润约80.7亿元，同比增加7.04%；归母扣非净利润79.15亿元，同比增长5.4%。智飞生物并未在一季报中直接说明原因。从具体产品层面，九价HPV疫苗批签发量暴涨136.16%至3655.08万支，四价HPV疫苗下降26.27%至1034.34万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-04-23/doc-inasukhc0263939.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-04-23/doc-inasukhc0263939.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429972659","title":"图解智飞生物一季报：第一季度单季净利润同比减28.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429972659","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429972659?lang=zh_cn&edition=full","pubTime":"2024-04-23 01:49","pubTimestamp":1713808199,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物2024年一季报显示，公司主营收入113.96亿元，同比上升2.0%；归母净利润14.58亿元，同比下降28.26%；扣非净利润14.55亿元，同比下降28.36%；负债率39.02%，财务费用596.36万元，毛利率26.05%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300002281.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429971184","title":"图解智飞生物年报：第四季度单季净利润同比减20.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429971184","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429971184?lang=zh_cn&edition=full","pubTime":"2024-04-23 00:43","pubTimestamp":1713804236,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物2023年年报显示，公司主营收入529.18亿元，同比上升38.3%；归母净利润80.7亿元，同比上升7.04%；扣非净利润79.15亿元，同比上升5.4%；其中2023年第四季度，公司单季度主营收入136.46亿元，同比上升30.7%；单季度归母净利润15.4亿元，同比下降20.31%；单季度扣非净利润15.35亿元，同比下降20.03%；负债率37.28%，财务费用4721.82万元，毛利率26.92%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300000716.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429927309","title":"智飞生物(300122.SZ)发布一季度业绩，净利润14.58亿元，同比下降28.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429927309","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429927309?lang=zh_cn&edition=full","pubTime":"2024-04-22 22:25","pubTimestamp":1713795900,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 智飞生物(300122.SZ)发布2024年第一季度报告，公司营业收入113.96亿元，同比增长2.00%;归属于上市公司股东的净利润14.58亿元，同比下降28.26%;归属于上市公司股东的扣除非经常性损益的净利润14.55亿元，同比下降28.36%;基本每股收益0.6090元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107170.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429922703","title":"智飞生物最新公告：一季度净利润14.58亿元 同比下降28.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429922703","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429922703?lang=zh_cn&edition=full","pubTime":"2024-04-22 22:20","pubTimestamp":1713795606,"startTime":"0","endTime":"0","summary":"智飞生物公布2024年一季度报告，报告期营业收入113.96亿元，同比增长2.00%；归属于上市公司股东的净利润14.58亿元，同比下降28.26%；基本每股收益0.6090元。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200030367.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429924842","title":"智飞生物最新公告：2023年归母净利润80.7亿元 同比增长7.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429924842","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429924842?lang=zh_cn&edition=full","pubTime":"2024-04-22 21:50","pubTimestamp":1713793828,"startTime":"0","endTime":"0","summary":"智飞生物发布2023年年度报告，报告期内，公司实现营业收入529.18亿元，较上年同期增长38.30%；实现归属于上市公司股东的净利润80.70亿元，较上年同期增长7.04%。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200029921.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429892247","title":"智飞生物：2023年归母净利润80.7亿元，同比增长7.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429892247","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2429892247?lang=zh_cn&edition=full","pubTime":"2024-04-22 21:48","pubTimestamp":1713793680,"startTime":"0","endTime":"0","summary":"格隆汇4月22日｜智飞生物发布2023年年度报告，报告期内，公司实现营业收入529.18亿元，较上年同期增长38.30%；实现归属于上市公司股东的净利润80.70亿元，较上年同期增长7.04%；实现归属于上市公司股东的扣除非经常性损益的净利润79.15亿元，较上年同期增长5.40%。               \n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-22/doc-inastpas9734426.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-22/doc-inastpas9734426.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422994111","title":"智飞生物(300122.SZ)完成回购 累计耗资3亿元回购621.03万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422994111","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422994111?lang=zh_cn&edition=full","pubTime":"2024-03-28 21:10","pubTimestamp":1711631400,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告，公司股份回购已实施完成，公司累计通过回购专用证券账户以集中竞价交易方式回购公司股份621.03万股，占公司当前总股本的0.26%，成交总金额为3亿元(不含交易费用)。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-28/doc-inapwvcn5354176.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-28/doc-inapwvcn5354176.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2420428870","title":"智飞生物(300122.SZ)首次回购131.67万股 耗资6584.26万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420428870","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2420428870?lang=zh_cn&edition=full","pubTime":"2024-03-18 17:17","pubTimestamp":1710753420,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告，2024年3月15日，公司通过回购专用证券账户以集中竞价交易方式首次回购公司股份131.67万股，占公司当前总股本的0.05%，最高成交价为50.34元/股，最低成交价为49.80元/股，成交总金额为人民币6584.26万元(不含交易费用)。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-18/doc-inantvpn5374408.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-18/doc-inantvpn5374408.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2416903610","title":"山河药辅与智飞生物合作开发注射产品？公司回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2416903610","media":"中证报","top":-1,"share":"https://www.laohu8.com/m/news/2416903610?lang=zh_cn&edition=full","pubTime":"2024-03-01 21:10","pubTimestamp":1709298600,"startTime":"0","endTime":"0","summary":"3月1日，针对“山河药辅与智飞生物合作开发注射产品”的市场传闻，山河药辅证券部工作人员对中国证券报·中证金牛座记者独家表示，公司注射剂辅料还没有经过CDE的关联审评（即药品监督管理局的一致性评价），与客户的合作都停留在样品开发阶段。\n　　上述工作人员称，注射剂辅料关联审评没有通过，就不能形成实质性订单，目前还都是样品。下游客户用公司注射剂做试验样品很常见，很多大型药企都是公司的客户。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：王其霖","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/2024-03-01/doc-inakvqye7357816.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/2024-03-01/doc-inakvqye7357816.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-09-28","address":"重庆市江北区庆云路1号50层","stockEarnings":[{"period":"1week","weight":0.0507},{"period":"1month","weight":-0.1853},{"period":"3month","weight":-0.2898},{"period":"6month","weight":-0.418},{"period":"1year","weight":-0.2781},{"period":"ytd","weight":-0.3965}],"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","perCapita":"13888股","boardName":"医药制造业","registeredCapital":"239378万元","compareEarnings":[{"period":"1week","weight":0.0138},{"period":"1month","weight":0.0256},{"period":"3month","weight":0.1124},{"period":"6month","weight":0.0309},{"period":"1year","weight":-0.0728},{"period":"ytd","weight":0.0581}],"survey":"　　重庆智飞生物制品股份有限公司是一家从事疫苗、生物制品的研发、生产和销售的公司；公司的主要产品包括预防流脑、宫颈癌、肺炎、轮状病毒等传染病的疫苗产品，也涵盖提供结核感染诊断、预防、治疗有效解决方案的药品。公司自成立以来，一贯注重研发与技术创新，通过十余年稳步增长的研发投入和持续深入的研发活动，形成了行业较领先的研发技术能力，并为公司可持续发展提供了技术根基。先后参与了科技部“863计划”,“现代医学技术”项目,科技部重大新药创制,国家新药创制重大专项等20余项国家级,省部级项目。","serverTime":1715150510276,"listedPrice":37.98,"stockholders":"101834人(较上一季度增加4.97%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}